Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$78.36 USD

78.36
6,753,643

+0.23 (0.29%)

Updated Jul 29, 2024 04:00 PM ET

After-Market: $78.35 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (185 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News

by Kinjel Shah

AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results. Merck (MRK) and Pfizer's (PFE) phase III studies achieve primary goals.

Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised

by Zacks Equity Research

Sanofi (SNY) posts mixed quarterly results, beating estimates for earnings while missing the same for sales. It raises its 2024 earnings growth expectations at CER.

Astrazeneca (AZN) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View

by Zacks Equity Research

AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.

The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences

by Zacks Equity Research

Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.

Kinjel Shah headshot

Should You Buy, Sell or Hold Merck (MRK) Ahead of Q2 Earnings?

by Kinjel Shah

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports second-quarter 2024 earnings.

Ahan Chakraborty headshot

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

by Ahan Chakraborty

Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.

Kinjel Shah headshot

Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?

by Kinjel Shah

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC

by Zacks Equity Research

Bristol Myers' (BMY) application seeking approval for Opdivo, in combination with Yervoy, for the indication of advanced hepatocellular carcinoma gets validation in the EU.

Ionis (IONS) Completes Enrolment for Rare Disease Drug Study

by Zacks Equity Research

Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.

Kinjel Shah headshot

AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?

by Kinjel Shah

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several candidates having blockbuster potential.

Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Astrazeneca (AZN) stood at $79.76, denoting a +1.49% change from the preceding trading day.

FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug

by Zacks Equity Research

The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20.

Here's Why Astrazeneca (AZN) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

The Zacks Analyst Blog Highlights Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian

by Zacks Equity Research

Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Novo Nordisk, AbbVie & AstraZeneca

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AbbVie Inc. (ABBV) and AstraZeneca PLC (AZN), as well as two micro-cap stocks, Air T, Inc. (AIRT) and United-Guardian, Inc. (UG).

Is JPMorgan Diversified Return International Equity ETF (JPIN) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JPIN

The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche

by Zacks Equity Research

Eli Lilly, Sanofi Merck, AstraZeneca's and Roche are included in this Analyst Blog.

AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC

by Zacks Equity Research

The European Commission approves AstraZeneca's (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based on data from the phase III FLAURA2 study.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD

by Kinjel Shah

Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.

AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use

by Zacks Equity Research

The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Kinjel Shah headshot

Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN

by Kinjel Shah

FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.

Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection

by Zacks Equity Research

The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.